Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
Journal of gastrointestinal oncology
View this publicationJournal of gastrointestinal oncology
View this publicationEuropean heart journal. Digital health
View this publicationThe Journal of infectious diseases
View this publicationFrontiers in psychiatry
View this publicationFrontiers in immunology
View this publicationMicrobiology spectrum
View this publicationJournal of cancer research and clinical oncology
View this publicationInternational journal of molecular sciences
View this publicationBiochimica et biophysica acta. General subjects
View this publicationNature immunology
View this publication